Bristol Joins List Of Merger Targets As Rx Stocks Stumble In First Quarter
Executive Summary
Bristol-Myers Squibb has joined a growing list of pharmaceutical companies that may need to complete a merger to retain their stock market valuations.You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
Shire Hopes To Sow Future Deals With $50M Venture Fund
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: